Clinical trials for Broken leg

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Broken leg. For all clinical trials, go to clinical trials search

This list shows clinical trials for Broken leg

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Broken leg
Title Recruitment status Location
study to the evaluate non-inferiority Compared two local anesthetic for orthopedic procedures on the lower limbs Not Recruiting Brazil
FONDAparinux in patients with a plaster CAST (FONDACAST): A Multicentre, Randomized, Open-label, Controlled, Two-Parallel-Group, Phase III Study to Evaluate the Efficacy and Safety of Fondaparinux versus Low-molecular-Weight Heparin (Nadroparin), in Patients Requiring Rigid or Semi-rigid Immobilization for at least 21 Days and up to 45 Days because of Isolated Non-surgical Below-Knee Injury - FONDACAST Not Recruiting France
FONDAparinux in patients with a plaster CAST (FONDACAST): A Multicentre, Randomized, Open-label, Controlled, Two-Parallel-Group, Phase III Study to Evaluate the Efficacy and Safety of Fondaparinux versus Low-molecular-Weight Heparin (Nadroparin), in Patients Requiring Rigid or Semi-rigid Immobilization for at least 21 Days and up to 45 Days because of Isolated Non-surgical Below-Knee Injury - FONDACAST Not Recruiting Germany
FONDAparinux in patients with a plaster CAST (FONDACAST): A Multicentre, Randomized, Open-label, Controlled, Two-Parallel-Group, Phase III Study to Evaluate the Efficacy and Safety of Fondaparinux versus Low-molecular-Weight Heparin (Nadroparin), in Patients Requiring Rigid or Semi-rigid Immobilization for at least 21 Days and up to 45 Days because of Isolated Non-surgical Below-Knee Injury - FONDACAST Not Recruiting Italy
FONDAparinux in patients with a plaster CAST (FONDACAST): A Multicentre, Randomized, Open-label, Controlled, Two-Parallel-Group, Phase III Study to Evaluate the Efficacy and Safety of Fondaparinux versus Low-molecular-Weight Heparin (Nadroparin), in Patients Requiring Rigid or Semi-rigid Immobilization for at least 21 Days and up to 45 Days because of Isolated Non-surgical Below-Knee Injury - FONDACAST Not Recruiting Netherlands
FONDAparinux in patients with a plaster CAST (FONDACAST): A Multicentre, Randomized, Open-label, Controlled, Two-Parallel-Group, Phase III Study to Evaluate the Efficacy and Safety of Fondaparinux versus Low-molecular-Weight Heparin (Nadroparin), in Patients Requiring Rigid or Semi-rigid Immobilization for at least 21 Days and up to 45 Days because of Isolated Non-surgical Below-Knee Injury - FONDACAST Not Recruiting Spain
FONDAparinux in patients with a plaster CAST (FONDACAST): A Multicentre, Randomized, Open-label, Controlled, Two-Parallel-Group, Phase III Study to Evaluate the Efficacy and Safety of Fondaparinux versus Low-molecular-Weight Heparin (Nadroparin), in Patients Requiring Rigid or Semi-rigid Immobilization for at least 21 Days and up to 45 Days because of Isolated Non-surgical Below-Knee Injury - FONDACAST Not Recruiting France
FONDAparinux in patients with a plaster CAST (FONDACAST): A Multicentre, Randomized, Open-label, Controlled, Two-Parallel-Group, Phase III Study to Evaluate the Efficacy and Safety of Fondaparinux versus Low-molecular-Weight Heparin (Nadroparin), in Patients Requiring Rigid or Semi-rigid Immobilization for at least 21 Days and up to 45 Days because of Isolated Non-surgical Below-Knee Injury - FONDACAST Not Recruiting Germany
FONDAparinux in patients with a plaster CAST (FONDACAST): A Multicentre, Randomized, Open-label, Controlled, Two-Parallel-Group, Phase III Study to Evaluate the Efficacy and Safety of Fondaparinux versus Low-molecular-Weight Heparin (Nadroparin), in Patients Requiring Rigid or Semi-rigid Immobilization for at least 21 Days and up to 45 Days because of Isolated Non-surgical Below-Knee Injury - FONDACAST Not Recruiting Italy
FONDAparinux in patients with a plaster CAST (FONDACAST): A Multicentre, Randomized, Open-label, Controlled, Two-Parallel-Group, Phase III Study to Evaluate the Efficacy and Safety of Fondaparinux versus Low-molecular-Weight Heparin (Nadroparin), in Patients Requiring Rigid or Semi-rigid Immobilization for at least 21 Days and up to 45 Days because of Isolated Non-surgical Below-Knee Injury - FONDACAST Not Recruiting Netherlands

Page last reviewed: 31/07/2015

Next review due: 01/07/2018